Arcellx Inc (NASDAQ:ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company’s multiple myeloma phase 2 trial.
On June 16, a clinical hold was placed after a patient death. Arcellx believes limitations on bridging therapy are a factor and is working with the FDA to expand patient options. Arcellx has FDA clearance to continue dosing lymphodepleted patients.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased